The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Morepen Labs successfully raised Rs. 200 Crore through QIP
Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024
Vimta Labs has reported total income of Rs. 82.44 crores during the period ended June 30, 2024
Laurus Labs receives EIR from USFDA for API facilities
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
The company has posted net profit of Rs.357.7 crores for the Financial Year ended March 31, 2024
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
